Altimmune ( ($ALT) ) has released its Q2 earnings. Here is a breakdown of the information Altimmune presented to its investors. Altimmune, Inc. is ...

Altimmune Inc (ALT) reports a robust cash reserve and significant progress in drug trials, despite ongoing financial losses ...

Altimmune (NASDAQ:ALT) shares rose on Tuesday after the company reported promising Q2 results banking on its experimental candidate, pemvidutide. Pemvidutide is in development for the treatment of ...

Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic ...

Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors ...

Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent ...

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise ...

Under these assumptions, Altimmune could have an estimated revenue of around $2.3B ($77B X 3 %). In my opinion, this could be a conservative estimate of the possible Pemvidutide sales in 6 years.

Altimmune has gone all-in on pemvidutide, a GLP-1/glucagon dual receptor agonist, and has the potential to secure blockbuster status, but they run the risk of regulatory failure.

The firm, which argues that pemvidutide "appears differentiated among GLP-1 compounds," reiterates a Buy rating and $12 price target on Altimmune shares.Published first on TheFly – the ultimate ...

--Altimmune, Inc., a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic ...